Similar articles

• In vitro correction of a pseudoexon-generating deep intronic mutation in LGMD2A by antisense oligonucleotides and modified small nuclear RNAs.

  Blázquez L, Aiastui A, Goicoechea M, Martins de Araujo M, Avril A, Beley C, García L, Valcárcel J, Fortes P, López de Munain A. Blázquez L, et al. Hum Mutat. 2013 Oct;34(10):1387-95. doi: 10.1002/humu.22379. Epub 2013 Aug 7. Hum Mutat. 2013. PMID: 23864287
• Antisense oligonucleotide treatment for a pseudoexon-generating mutation in the NPC1 gene causing Niemann-Pick type C disease.

  Rodríguez-Pascau L, Coll MJ, Vilageliu L, Grinberg D. Rodríguez-Pascau L, et al. Hum Mutat. 2009 Nov;30(11):E993-E1001. doi: 10.1002/humu.21119. Hum Mutat. 2009. PMID: 19718781
• DMD pseudoexon mutations: splicing efficiency, phenotype, and potential therapy.

  Gurvich OL, Tuohy TM, Howard MT, Finkel RS, Medne L, Anderson CB, Weiss RB, Wilton SD, Flanigan KM. Gurvich OL, et al. Ann Neurol. 2008 Jan;63(1):81-9. doi: 10.1002/ana.21290. Ann Neurol. 2008. PMID: 18059005
• A novel dysferlin mutant pseudoexon bypassed with antisense oligonucleotides.

  Dominov JA, Uyan O, Sapp PC, McKenna-Yasek D, Nallamilli BR, Hegde M, Brown RH Jr. Dominov JA, et al. Ann Clin Transl Neurol. 2014 Sep;1(9):703-20. doi: 10.1002/acn3.96. Epub 2014 Sep 27. Ann Clin Transl Neurol. 2014. PMID: 25493284 Free PMC article.
• Pseudoexon activation increases phenotype severity in a Becker muscular dystrophy patient.

  Greer K, Mizzi K, Rice E, Kuster L, Barrero RA, Bellgard MI, Lynch BJ, Foley AR, O Rathallaigh E, Wilton SD, Fletcher S. Greer K, et al. Mol Genet Genomic Med. 2015 Jul;3(4):320-6. doi: 10.1002/mgg3.144. Epub 2015 Apr 15. Mol Genet Genomic Med. 2015. PMID: 26247048 Free PMC article.